Table 2.
The associations between blood NfL levels and clinical variables in NMOSD patients at baseline.
| Variable | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| exp(β) value | 95% CI | p value | exp(β) value | 95% CI | p value | |
| Age at baseline | 1.01 | 0.74–1.40 | <0.001 | 1.01 | 1.00–1.01 | 0.017 |
| Sex (Ref = female) | 1.26 | 0.91–1.74 | 0.162 | Not included | ||
| EDSS | 1.11 | 1.08–1.15 | <0.001 | 1.06 | 1.02–1.09 | 0.002 |
| ARR | 0.94 | 0.80–1.11 | 0.470 | Not included | ||
| Number of relapse event | 1.00 | 0.96–1.04 | 0.888 | Not included | ||
| Disease duration | 1.00 | 0.98–1.02 | 0.983 | Not included | ||
| Recent relapse (<60d) | ||||||
| No | Ref | |||||
| Yes | 1.73 | 1.47–2.04 | <0.001 | 1.37 | 1.14–1.63 | <0.001 |
| Treatment at baseline | ||||||
| No treatment a | Ref | |||||
| Treated | 0.62 | 0.51–0.75 | <0.001 | 0.90 | 0.75–1.08 | 0.253 |
ARR, Annualized relapse rates; CI, confidence interval; DMD, Disease-Modifying Drug; EDSS, Expanded Disability Status Scale; NfL, neurofilament light chain; NMOSD, neuromyelitis optica spectrum disorders; pNfL, plasma neurofilament light chain; Ref, reference.
No treatment was defined as patients who first diagnosed, or at relapse stage did not receive any prior treatment, including high dose intravenous steroids, plasma exchange (PE), intravenous immunoglobulin (IVIG), or any DMD treatment at baseline; Univariable estimates are given for all tested variables, multivariable estimates are only provided for the variables used in the final multiple lineal model; the estimates β were back transformed (exp(β)) because dependent variable pNfL was log-transformed.